Is Toradol Stronger Than Ibuprofen?
No, ketorolac (Toradol) is not meaningfully "stronger" than ibuprofen for most acute pain conditions—recent high-quality evidence demonstrates comparable analgesic efficacy between these two NSAIDs, though ketorolac carries greater gastrointestinal toxicity risk and is restricted to short-term use (≤5 days). 1
Evidence-Based Comparison
Analgesic Efficacy: Essentially Equivalent
Multiple recent randomized controlled trials demonstrate no clinically significant difference in pain relief:
Acute musculoskeletal back pain (2025): Oral ibuprofen 400 mg provided identical pain reduction to intramuscular ketorolac 10 mg at 1 hour (VAS reduction: 35 vs 32 points, 95% CI: -8.03 to 15.03) 2
Postoperative pain after hysterectomy (2024): Intravenous ibuprofen 800 mg and ketorolac 30 mg produced similar 24-hour pain scores with no difference in opioid requirements 3
Pediatric trauma pain (2023): Oral ibuprofen 10 mg/kg and ketorolac 0.5 mg/kg showed equivalent pain reduction at 60 minutes in children with moderate-to-severe traumatic pain 4
Acute low back pain (2021): While functional improvement (RMDQ scores) was similar across groups, ketorolac showed a trend toward better pain relief (80% with mild/no pain) versus ibuprofen (62%), though this required treating 6 patients to benefit one additional patient 5
A 2024 meta-analysis of six RCTs confirmed 24-hour opioid consumption was comparable between IV ibuprofen and IV ketorolac (mean difference: -4.72 mg; P=0.79) 6
Critical Safety Differences
Ketorolac carries significantly higher gastrointestinal toxicity risk compared to ibuprofen. The 2006 consensus guideline identifies ketorolac among NSAIDs with "greater GI toxicity related to prolonged gastric and duodenal mucosal exposure" due to its prolonged half-life 7. In the 2021 low back pain trial, stomach irritation occurred in 26% of ibuprofen patients versus only 5% with ketorolac 5—though this finding is counterintuitive and may reflect route of administration differences.
Among NSAIDs, ibuprofen demonstrates superior GI safety in comparative studies 7.
Regulatory Restrictions Matter
The FDA mandates ketorolac use be limited to ≤5 days total (IV/IM plus oral combined) specifically because of increased frequency and severity of adverse reactions with longer duration 1. Ketorolac is indicated only for "moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting" 1.
Ibuprofen has no such duration restrictions for acute pain management 8.
Clinical Algorithm for NSAID Selection
Choose ibuprofen (400-800 mg every 6-8 hours) when:
- Pain duration expected >5 days
- Patient has GI risk factors (prior ulcer, age >65, concurrent anticoagulation, corticosteroid use)
- Outpatient management of acute musculoskeletal pain
- Pediatric patients with trauma pain
Consider ketorolac (10-30 mg IV/IM or 10 mg PO) only when:
- Severe acute postoperative pain in first 1-2 days
- Patient cannot tolerate oral medications initially
- You can guarantee treatment duration ≤5 days
- No contraindications (renal impairment, bleeding risk, prior peptic ulcer)
Common Pitfalls to Avoid
Don't assume parenteral = more potent: The route of administration doesn't make ketorolac inherently stronger—oral ibuprofen 400 mg matches IM ketorolac 10 mg 2
Don't exceed 5-day limit with ketorolac: The FDA black box warning exists because serious adverse events increase significantly beyond this timeframe 1
Don't ignore GI risk stratification: Ketorolac's prolonged half-life increases mucosal exposure time. Patients with any GI risk factors should receive ibuprofen instead 7
Don't combine with aspirin: Both NSAIDs plus aspirin increases GI bleeding risk >10-fold 7
Don't use ketorolac as first-line outpatient therapy: Guidelines support oral NSAIDs (including ibuprofen) as appropriate first-line treatment for acute musculoskeletal pain 9